Ceftriaxone

Generic Name: Ceftriaxone

Brand Names: Rocephin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈N_₈O_₇S_₃

CAS Number: 73384-59-5

Unique Ingredient Identifier: 75J73V1629

Background: Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S...

Indication: Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabil...

Associated Conditions: Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial

Associated Therapies: -

Clinical Trials

Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth

Phase 4

Not yet recruiting

Conditions: Bacterial Vaginosis
Vaginal Dysbiosis
Premature Delivery

Interventions: Diagnostic Test: Vaginal flora abnormalities screening and quantification using molecular biology technique
Other: Usual Care
Drug: Azithromycine
Drug: Ceftriaxone
Drug: Metronidazole
Drug: Clotrimazole, Vaginal

First Posted Date: 2024-04-05

Last Posted Date: 2024-04-05

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 1292

Registration Number: NCT06349122

Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury

Phase 4

Not yet recruiting

Conditions: Sepsis
Liver Dysfunction

Interventions: Drug: Saline
Drug: Mecobalamin
Drug: Placebo
Drug: Ceftriaxone Sodium

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Sichuan Provincial People's Hospital

Target Recruit Count: 40

Registration Number: NCT06220929

Locations: 🇨🇳
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline

Phase 4

Recruiting

Conditions: Early Syphilis

Interventions: Drug: Doxycycline
Drug: Ceftriaxone
Drug: benzathine penicillin G

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 300

Registration Number: NCT05980871

Locations: 🇨🇳
Kuan-Yin Lin, Taipei, Taiwan

Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study

Phase 3

Not yet recruiting

Conditions: Neisseria Gonorrhoeae Infection
Asymptomatic Pharyngeal Carriage

Interventions: Other: Absence of antibiotic treatment
Drug: Ceftriaxone

First Posted Date: 2023-08-02

Last Posted Date: 2023-08-02

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 254

Registration Number: NCT05971550

Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma

Phase 3

Recruiting

Conditions: Antibiotic Prophylaxis

Interventions: Drug: Ceftriaxone Sodium

First Posted Date: 2022-12-16

Last Posted Date: 2022-12-16

Lead Sponsor: Nadeem Iqbal

Target Recruit Count: 158

Registration Number: NCT05654896

Locations: 🇵🇰
Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan

Antibiotic Instillation in Appendicitis

Phase 2

Completed

Conditions: Complicated Appendicitis
Acute Appendicitis

Interventions: Procedure: Intra-peritoneal Fluid Aspiration
Drug: Ceftriaxone

First Posted Date: 2022-07-22

Last Posted Date: 2024-11-06

Lead Sponsor: Johns Hopkins All Children's Hospital

Target Recruit Count: 32

Registration Number: NCT05470517

Locations: 🇺🇸
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States

Propranolol on Post Stroke Immune Status and Infection

Phase 2

Conditions: Ischemic Stroke
Propranolol
Physiological Effects of Drugs
Nervous System Diseases
Cerebrovascular Disorders
Brain Diseases
Stroke
Central Nervous System Diseases
Immunologic Factors
Cardiovascular Diseases

Interventions: Drug: Propranolol
Drug: Ceftriaxone

First Posted Date: 2022-05-16

Last Posted Date: 2022-05-16

Lead Sponsor: Tianjin Medical University General Hospital

Target Recruit Count: 45

Registration Number: NCT05375240

Locations: 🇨🇳
Beijing Tiantan Hospital, Beijing, China
🇨🇳
Tianjin Medical University General Hospital, Tianjin, China

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Phase 2

Recruiting

Conditions: Gonorrhea Male

Interventions: Drug: Cefixime
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090
Biological: Meningococcal Group B Vaccine
Biological: Influenza Vaccine
Biological: Tetanus-diptheria Vaccine

First Posted Date: 2022-03-24

Last Posted Date: 2023-05-24

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 140

Registration Number: NCT05294588

Locations: 🇺🇸
Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States